Milnacipran: A comparative analysis of human monoamine uptake and transporter binding affinity

被引:127
作者
Vaishnavi, SN
Nemeroff, CB
Plott, SJ
Rao, SG
Kranzler, J
Owens, MJ [1 ]
机构
[1] Emory Univ, Dept Psychiat & Behav Sci, Lab Neuropsychopharmacol, Atlanta, GA 30332 USA
[2] Cypress Biosci, San Diego, CA USA
关键词
human serotonin transporter; milnacipran; human dopamine transporter; human norepinephrine transporter; monoamine uptake; transporter binding;
D O I
10.1016/j.biopsych.2003.07.006
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Background: Though selective serotonin reuptake inhibitors have revolutionized the field of psychiatry with demonstrated efficacy in affective and anxiety disorders with minimal side effects, norepinephrine-serotonin reuptake inhibitors may provide efficacy similar to tricyclic antidepressants without the adverse side effects associated with tricyclic antidepressants. Methods: The affinity and selectivity of milnacipran, duloxetine, venlafaxine, citalopram, amitriptyline, and nortriptyline were determined for the human serotonin, norepinephrine, and dopamine transporters. Results. Both milnacipran and duloxetine were potent inhibitors of serotonin and norepinephrine uptake. Unlike duloxetine and venlafaxine, milnacipran appears serotonin transporter selective in binding (ratio = 2.61) and norepinephrine transporter selective in uptake (ratio =.45). Conclusions. Milnacipran's binding and uptake inhibition profile more closely resembles that of the tricyclic antidepressants than that of duloxetine. Whether these differences observed in vitro manifest themselves in vivo is not clear.
引用
收藏
页码:320 / 322
页数:3
相关论文
共 15 条
[1]  
Andersson B., 1987, Nuclear Physics A, VA461, p513c, DOI 10.1016/0375-9474(87)90510-0
[2]   Affinities of venlafaxine and various reuptake inhibitors for the serotonin and norepinephrine transporters [J].
Béïque, JC ;
Lavoie, N ;
de Montigny, C ;
Debonnel, G .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1998, 349 (01) :129-132
[3]   Preclinical pharmacology of milnacipran [J].
Briley, M ;
Prost, JF ;
Moret, C .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1996, 11 :9-14
[4]   Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors [J].
Bymaster, FP ;
Dreshfield-Ahmad, LJ ;
Threlkeld, PG ;
Shaw, JL ;
Thompson, L ;
Nelson, DL ;
Hemrick-Luecke, SK ;
Wong, DT .
NEUROPSYCHOPHARMACOLOGY, 2001, 25 (06) :871-880
[5]  
ENGLEMAN EA, 1995, NEUROPSYCHOPHARMACOL, V12, P287, DOI 10.1016/0893-133X(94)00093-F
[6]   Inhibition of norepinephrine uptake in patients with major depression treated with paroxetine [J].
Gilmor, ML ;
Owens, MJ ;
Nemeroff, CB .
AMERICAN JOURNAL OF PSYCHIATRY, 2002, 159 (10) :1702-1710
[7]   Effect of acute, short- and long-term milnacipran administration on rat locus coeruleus noradrenergic and dorsal raphe serotonergic neurons [J].
Mongeau, R ;
Weiss, M ;
de Montigny, C ;
Blier, P .
NEUROPHARMACOLOGY, 1998, 37 (07) :905-918
[8]  
Moret C, 1997, J NEUROCHEM, V69, P815
[9]   BIOCHEMICAL PROFILE OF MIDALCIPRAN (F-2207), 1-PHENYL-1-DIETHYL-AMINOCARBONYL-2-AMINOMETHYL-CYCLOPROPANE (Z) HYDROCHLORIDE, A POTENTIAL 4TH GENERATION ANTIDEPRESSANT DRUG [J].
MORET, C ;
CHARVERON, M ;
FINBERG, JPM ;
COUZINIER, JP ;
BRILEY, M .
NEUROPHARMACOLOGY, 1985, 24 (12) :1211-1219
[10]   Second-generation SSRIs:: Human monoamine transporter binding profile of escitalopram and R-fluoxetine [J].
Owens, MJ ;
Knight, DL ;
Nemeroff, CB .
BIOLOGICAL PSYCHIATRY, 2001, 50 (05) :345-350